Advances in targeting estrogen synthesis and receptors in patients with endometriosis

References

• Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019;40(4):1048–1079.
   PubMed Web of Science ®Google Scholar
• Saunders PTK, Horne AW. Endometriosis: etiology, pathobiology, and therapeutic prospects. Cell. 2021 May;184(11):2807–2824.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Granese R, et al. Clinical dynamics of dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):593–596.
   PubMed Web of Science ®Google Scholar
• Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–682.
   PubMed Web of Science ®Google Scholar
• Giudice LC, Kao LC. Endometriosis. Lancet. 2004 Nov;364(9447):1789–1799.
   PubMed Web of Science ®Google Scholar
• Liang Y, Yao S. Potential role of estrogen in maintaining the imbalanced sympathetic and sensory innervation in endometriosis. Mol Cell Endocrinol. 2016;424:42–49.
   PubMed Web of Science ®Google Scholar
• Lai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci. 2019;15(13):2783–2797.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Vitale SG, Trovato MA, et al. Full-thickness excision versus shaving by laparoscopy for intestinal deep infiltrating endometriosis: rationale and potential treatment options. Biomed Res Int. 2016;2016:1–8.
   Web of Science ®Google Scholar
• Raffaelli R, Garzon S, Baggio S, et al. Mesenteric vascular and nerve sparing surgery in laparoscopic segmental intestinal resection for deep infiltrating endometriosis. Eur J Obstet Gynecol. 2018 Dec;231:214–219.
   PubMed Web of Science ®Google Scholar
• Vannuccini S, Clemenza S, Rossi M, et al. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2021 Aug; 23(3):333–355.
   PubMed Web of Science ®Google Scholar
• Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020;26(4):565–585.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Utsunomiya H, Lin Z, et al. Steroidogenic factor-1 and endometriosis. Mol Cell Endocrinol. 2009;300(1–2):104–108.
   PubMed Web of Science ®Google Scholar
• Chantalat E, Valera MC, Vaysse C, et al. Estrogen receptors and endometriosis. Int J Mol Sci. 2020 Apr;21(8):2815.
   PubMed Web of Science ®Google Scholar
• Han SJ, O’Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014;20(4):467–484.
   PubMed Web of Science ®Google Scholar
• Chen H, Malentacchi F, Fambrini M, et al. Epigenetics of estrogen and progesterone receptors in endometriosis. Reprod Sci. 2020;27(11):1967–1974.
   PubMed Web of Science ®Google Scholar
• Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007;77(4):681–687.
   PubMed Web of Science ®Google Scholar
• Tang ZR, Zhang R, Lian ZX, et al. Estrogen-receptor expression and function in female reproductive disease. Cells. 2019;8(10):1–15.
   Web of Science ®Google Scholar
• Burns KA, Rodriguez KF, Hewitt SC, et al. Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model. Endocrinology. 2012 Aug;153(8):3960–3971.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1):39–45.
   PubMed Web of Science ®Google Scholar
• Patel B, Elguero S, Thakore S, et al. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21(2):155–173.
   PubMed Web of Science ®Google Scholar
• Han SJ, Jung SY, Wu SP, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell. 2015;163(4):960–974.
   PubMed Web of Science ®Google Scholar
• Monsivais D, Dyson MT, Yin P, et al. Estrogen receptor β regulates endometriotic cell survival through serum and glucocorticoid-regulated kinase activation. Fertil Steril. 2016 May;105(5):1266–1273.
   PubMed Web of Science ®Google Scholar
• Monsivais D, Dyson MT, Yin P, et al. ERβ- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. Mol Endocrinol. 2014;28(8):1304–1315.
   PubMedGoogle Scholar
• Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Mol Cell Endocrinol. 2007 Feb;265–266:138–142.
   PubMed Web of Science ®Google Scholar
• Plante BJ, Lessey BA, Taylor RN, et al. G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. Reprod Sci. 2012;19(7):684–693.
   PubMed Web of Science ®Google Scholar
• Della Corte L, Barra F, Mercorio A, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020;759–768.
   PubMed Web of Science ®Google Scholar
• Pluchino N, Freschi L, Wenger JM, et al. Innovations in classical hormonal targets for endometriosis. Expert Rev Clin Pharmacol. 2016;9(2):317–327.
   PubMed Web of Science ®Google Scholar
• Meresman GF, Bilotas M, Buquet RA, et al. Gonadotropin-releasing hormone agonist induces apoptosis and reduces cell proliferation in eutopic endometrial cultures from women with endometriosis. Fertil Steril. 2003 Sep;80(2):702–707.
   PubMedGoogle Scholar
• Tesone M, Bilotas M, Barañao RI, et al. The role of GnRH analogues in endometriosis-associated apoptosis and angiogenesis. Gynecol Obstet Invest. 2008;66(1):10–18.
   PubMedGoogle Scholar
• Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010 Dec 8; 2010(12):CD008475.
   PubMedGoogle Scholar
• Bergqvist A, Bergh T, Hogström L, et al. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998 Apr;69(4):702–708.
   PubMed Web of Science ®Google Scholar
• Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. 1990 Sep;54(3): 419–427.
   PubMed Web of Science ®Google Scholar
• Miller JD. Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. Am J Obstet Gynecol. 2000 Jun;182(6):1483–1488.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Bocciolone L, et al. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril. 1993 Mar;59(3):516–521.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006 Feb;85(2):314–325.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006 Jan;21(1):248–256.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010 Mar;25(3):633–641.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009 Mar;91(3):675–681.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005 Jul;20(7):1993–1998.
   PubMed Web of Science ®Google Scholar
• Ferreira RA, Vieira CS, Rosa-E-Silva JC, et al. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception. 2010 Feb;81(2):117–122.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492–496.
   PubMed Web of Science ®Google Scholar
• Lemay A, Maheux R, Huot C, et al. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988 Feb;158(2):233–236.
   PubMed Web of Science ®Google Scholar
• Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with buserelin or danazol in the management of endometriosis: a randomized, comparative study. Fertil Steril. 1989 Mar;51(3):395–400.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Tárrega E, Monzo AM, Quiroga R, et al. Effect of GnRH agonist before IVF on outcomes in infertile endometriosis patients: a randomized controlled trial. Reprod Biomed Online. 2020;41(4):653–662.
   PubMed Web of Science ®Google Scholar
• Berlanda N, Somigliana E, Viganò P, et al. Safety of medical treatments for endometriosis. Expert Opin Drug Saf. 2016 Jan;15(1):21–30.
   PubMed Web of Science ®Google Scholar
• Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril. 2004 Jan;81(1):149–153.
   PubMed Web of Science ®Google Scholar
• Sagsveen M, Farmer JE, Prentice A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;2003(4):CD001297.
   PubMedGoogle Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992 Feb;166(2):740–745.
   PubMed Web of Science ®Google Scholar
• Tosti C, Biscione A, Morgante G, et al. Hormonal therapy for endometriosis: from molecular research to bedside. Eur J Obstet Gynecol Reprod Biol. 2017Feb;209:61–66.
   PubMed Web of Science ®Google Scholar
• Mitwally MFM, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9(4):236–241.
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril. 2006 Jul;86(1):220–222.
   PubMed Web of Science ®Google Scholar
• Clemenza S, Sorbi F, Noci I, et al. From pathogenesis to clinical practice: emerging medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018;51:92–101.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019;34(2):193–199.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans -M-M. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review. J Clin Med. 2021 Mar;10(5):1085.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Gnrh antagonists with or without add‐back therapy: a new alternative in the management of endometriosis? Int J Mol Sci. 2021;22(21):11342.
   PubMed Web of Science ®Google Scholar
• Leyland N, Estes SJ, Lessey BA, et al. A clinician’s guide to the treatment of endometriosis with elagolix. J Womens Health. 2021;30(4):569–578.
   Web of Science ®Google Scholar
• Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40.
   PubMed Web of Science ®Google Scholar
• Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis results from two extension studies. Obstet Gynecol. 2018;132(1):147–160.
   PubMed Web of Science ®Google Scholar
• Pokrzywinski RM, Soliman AM, Chen J, et al. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. Am J Obstet Gynecol. 2020 Jun;222(6):592.e1–592.e10.
   PubMed Web of Science ®Google Scholar
• Abrao MS, Surrey E, Gordon K, et al. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients. BMC Womens Health. 2021;21(1):1–14.
   PubMed Web of Science ®Google Scholar
• Surrey ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019 Aug;112(2):298–304.e3.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019 Mar;133(3):423–433.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019 Nov;112(5):922–929.e2.
   PubMed Web of Science ®Google Scholar
• Markham A. Relugolix: first global approval. Drugs. 2019 Apr;79(6):675–679.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021 Feb;115(2):397–405.
   Web of Science ®Google Scholar
• Harada T, Osuga Y, Suzuki Y, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2021 Dec;117(3):583–592.
   PubMed Web of Science ®Google Scholar
• As-Sanie S, Becker CM, Johnson N, et al. Efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: phase 3 randomized, double-blind, placebo-controlled study (Spirit 2). Fertil Steril. 2020;114(3):e77.
   PubMed Web of Science ®Google Scholar
• Zandvliet AS, Ouerdani A, Lee T-Y, et al. Simulated Long-term effects of relugolix combination therapy on bone mineral density at the lumbar spine as predicted by a validated semi-mechanistic exposure-response model. Fertil Steril. 2020;114(3):e350.
   Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44–55.
   PubMed Web of Science ®Google Scholar
• Dababou S, Garzon S, Laganà AS, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021;30(9):903–911.
   PubMed Web of Science ®Google Scholar
• Velasco I, Rueda J, Acién P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod. 2006 Jun;12(6):377–381.
   PubMed Web of Science ®Google Scholar
• Garzon S, Laganà AS, Barra F, et al. Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development. Expert Opin Investig Drugs. 2020;29(12):1377–1388.
   PubMed Web of Science ®Google Scholar
• Montagna P, Capellino S, Villaggio B, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril. 2008;90(1):156–164.
   PubMed Web of Science ®Google Scholar
• Huhtinen K, Desai R, Ståhle M, et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012 Nov;97(11):4228–4235.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Yang S, Fang Z, et al. Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol. 2001 Dec;79(1–5):19–25.
   PubMed Web of Science ®Google Scholar
• Patwardhan S, Nawathe A, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. 2008;115(7):818–822.
   PubMed Web of Science ®Google Scholar
• Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril. 2012 Dec;98(6):1370–1379.
   PubMed Web of Science ®Google Scholar
• Committee Opinion. 663: aromatase inhibitors in gynecologic practice. Obstet Gynecol. 2016;Jun 127(6):e170–4. No
   PubMed Web of Science ®Google Scholar
• Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril. 2005 Aug;84(2):300–304.
   PubMed Web of Science ®Google Scholar
• Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004 Jan;19(1):160–167.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod. 2009 Dec;24(12):3033–3041.
   PubMed Web of Science ®Google Scholar
• Ailawadi RK, Jobanputra S, Kataria M, et al. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004 Feb;81(2):290–296.
   PubMed Web of Science ®Google Scholar
• Razzi S, Fava A, Sartini A, et al. Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. BJOG. 2004 Feb;111(2):182–184.
   PubMed Web of Science ®Google Scholar
• Lossl K, Loft A, Freiesleben NLC, et al. Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. Eur J Obstet Gynecol Reprod Biol. 2009 May;144(1):48–53.
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. Biomed Res Int. 2015;2015:878517.
   PubMed Web of Science ®Google Scholar
• Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, Van Trotsenburg M, et al. Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril. 2005;84(4):1033–1036.
   PubMed Web of Science ®Google Scholar
• Nave R. Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective. Drug Deliv. 2019 Jan;26(1):586–594.
   PubMed Web of Science ®Google Scholar
• Rotgeri A, Korolainen H, Sundholm O, et al. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys. Hum Reprod. 2015 Feb;30(2):308–314.
   PubMed Web of Science ®Google Scholar
• Pohl O, Bestel E, Gotteland JP. Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase i proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014;21(10):1256–1265.
   PubMed Web of Science ®Google Scholar
• Purohit A, Fusi L, Brosens J, et al. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod. 2008 Feb;23(2):290–297.
   PubMed Web of Science ®Google Scholar
• Day JM, Tutill HJ, Purohit A, et al. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer. 2008 Sep;15(3):665–692.
   PubMed Web of Science ®Google Scholar
• Konings G, Brentjens L, Delvoux B, et al. Intracrine regulation of estrogen and other sex steroid levels in endometrium and non-gynecological tissues. Pathol Physiol and Drug Discovery. 2018;9. 940.
   Google Scholar
• Delvoux B, D’Hooghe T, Kyama C, et al. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. J Clin Endocrinol Metab. 2014;99(1):276–284.
   PubMed Web of Science ®Google Scholar
• Barra F, Romano A, Grandi G, et al. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. Expert Opin Investig Drugs. 2019;28(6):501–504.
   PubMed Web of Science ®Google Scholar
• van Hoesel MH, Chen YL, Zheng A, et al. Selective oestrogen receptor modulators (SERMs) for endometriosis. Cochrane Database Syst Rev. 2021 May;5(5):CD011169.
   PubMedGoogle Scholar
• Simsa P, Mihalyi A, Kyama CM, et al. Selective estrogen-receptor modulators and aromatase inhibitors: promising new medical therapies for endometriosis? Womens Health (Lond). 2007 Sep;3(5):617–628.
   PubMedGoogle Scholar
• Cho YH, Um MJ, Kim SJ, et al. Raloxifene administration in women treated with long term gonadotropin-releasing hormone agonist for severe endometriosis: effects on bone mineral density. J Menopausal Med. 2016 Dec;22(3):174–179.
   PubMedGoogle Scholar
• Altintas D, Kokcu A, Kandemir B, et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):84–87.
   PubMed Web of Science ®Google Scholar
• Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg. 2005;18(4):177–183.
   PubMed Web of Science ®Google Scholar
• Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008 Jan;111(1):88–96.
   PubMed Web of Science ®Google Scholar
• Naqvi H, Sakr S, Presti T, et al. Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. Biol Reprod. 2014 Jun;90(6):121.
   PubMed Web of Science ®Google Scholar
• Sakr S, Naqvi H, Komm B, et al. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. Endocrinology. 2014;155(4):1489–1497.
   PubMed Web of Science ®Google Scholar
• Flores VA, Stachenfeld NS, Taylor HS. Bazedoxifene-conjugated estrogens for treating endometriosis. Obstet Gynecol. 2018;132(2):475–477.
   PubMed Web of Science ®Google Scholar
• Lobo RA, V PJ, Gass MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009 Sep;92(3):1025–1038.
   PubMed Web of Science ®Google Scholar
• Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018;25(9):1033–1045.
   PubMed Web of Science ®Google Scholar
• Kulak JJ, Fischer C, Komm B, et al. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011 Aug;152(8):3226–3232.
   PubMed Web of Science ®Google Scholar
• Geiser AG, Hummel CW, Draper MW, et al. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology. 2005 Oct;146(10):4524–4535.
   PubMed Web of Science ®Google Scholar
• Saito T, Yoshizawa M, Yamauchi Y, et al. Effects of the novel orally active antiestrogen TZE-5323 on experimental endometriosis. Arzneimittelforschung. 2003;53(7):507–514.
   PubMed Web of Science ®Google Scholar
• Harada T, Ohta I, Endo Y, et al. SR-16234, a novel selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial. Yonago Acta Med. 2017 Dec;60(4):227–233.
   PubMed Web of Science ®Google Scholar
• Khine YM, Taniguchi F, Nagira K, et al. New insights into the efficacy of SR-16234, a selective estrogen receptor modulator, on the growth of murine endometriosis-like lesions. Am J Reprod Immunol. 2018 Nov;80(5):e13023.
   PubMed Web of Science ®Google Scholar
• Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology. 2003 Oct;144(10):4241–4249.
   PubMed Web of Science ®Google Scholar
• Harris HA, Bruner-Tran KL, Zhang X, et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod. 2005 Apr;20(4):936–941.
   PubMed Web of Science ®Google Scholar
• Leventhal L, Brandt MR, Cummons TA, et al. An estrogen receptor-β agonist is active in models of inflammatory and chemical-induced pain. Eur J Pharmacol. 2006;553(1–3):146–148.
   PubMed Web of Science ®Google Scholar
• Xiu-li W, Wen-jun C, Hui-hua D, et al. ERB-041, a selective ERβ agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-κB activation. Mol Immunol. 2009;46(11–12):2413–2418.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gong P, Chen Y, et al. Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci Transl Med. 2015 Jan;7(271):271ra9.
   PubMed Web of Science ®Google Scholar
• Wu J, Yan J, Fang P, et al. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism. Cancer Lett. 2020 Jan;469:78–88.
   PubMed Web of Science ®Google Scholar
• Imesch P, Samartzis EP, Dedes KJ, et al. Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells. Fertil Steril. 2013 Sep;100(3):770–776.
   PubMed Web of Science ®Google Scholar
• Becker CM, Bokor A, Heikinheimo O et al, , ESHRE guideline: endometriosis. Hum Reprod Open. 2022 Feb 26;2022(2):hoac009.
   PubMedGoogle Scholar
• Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014 Apr;101(4):927–935.
   PubMed Web of Science ®Google Scholar
• Bowers JL, Tyulmenkov VV, Jernigan SC, et al. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 2000 Oct;141(10):3657–3667.
   PubMed Web of Science ®Google Scholar
• Kolahdouz Mohammadi R, Arablou T. Resveratrol and endometriosis: in vitro and animal studies and underlying mechanisms (Review). Biomed Pharmacother. 2017 Jul;91:220–228.
   PubMed Web of Science ®Google Scholar
• Ozcan Cenksoy P, Oktem M, Erdem O, et al. A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model. Gynecol Endocrinol. 2015 Mar;31(3):219–224.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Guven S, Kirbas A, et al. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:1–6.
   PubMed Web of Science ®Google Scholar
• Ergenoğlu AM, Yeniel AÖ, Erbaş O, et al. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod Sci. 2013 Oct;20(10):1230–1236.
   PubMed Web of Science ®Google Scholar
• Greaves E, Cousins FL, Murray A, et al. A novel mouse model of endometriosis mimics human phenotype and reveals insights into the inflammatory contribution of shed endometrium. Am J Pathol. 2014;184(7):1930–1939.
   PubMed Web of Science ®Google Scholar